WC
KPTI icon

Wexford Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Wexford Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,819
Closed -$23.6K – 254
2023
Q4 		$23.6K Buy
+1,819
New +$24.5K 0.01% 183

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wexford Capital's KPTI Position: Q1 2024 in Review

Wexford Capital sold out of Karyopharm Therapeutics (KPTI) in Q1 2024, closing a stake of 1,819 shares — an estimated $23.6K sold.

Wexford Capital first reported a position in KPTI in Q4 2023 and held it in 1 quarter. The position peaked at $23.6K in Q4 2023. 113 funds tracked by Wall St. Rank hold KPTI as of Q1 2024.

  • Wexford Capital reported no remaining Karyopharm Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Wexford Capital sold 1,819 Karyopharm Therapeutics shares in Q1 2024, an estimated $23.6K.
  • Wexford Capital first reported a position in Karyopharm Therapeutics in Q4 2023 and held it in 1 quarter.
  • Wexford Capital's Karyopharm Therapeutics position peaked at $23.6K in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.